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Abstract
Background:  Axenfeld-Rieger syndrome (ARS) is characterized by bilateral congenital
abnormalities of the anterior segment of the eye associated with abnormalities of the teeth,
midface, and umbilicus. Most cases of ARS are caused by mutations in the genes encoding PITX2
or FOXC1. Here we describe a family affected by a severe form of ARS.
Case presentation: Two members of this family (father and daughter) presented with typical ARS
and developed severe glaucoma. The ocular phenotype was much more severe in the daughter than
in the father. Magnetic resonance imaging (MRI) detected an aggressive form of meningioma in the
father. There was no mutation in the PITX2 gene, determined by exon screening. We identified an
intragenic deletion by quantitative genomic PCR analysis and characterized this deletion in detail.
Conclusion:  Our findings implicate the first intragenic deletion of the PITX2  gene in the
pathogenesis of a severe form of ARS in an affected family. This study stresses the importance of a
systematic search for intragenic deletions in families affected by ARS and in sporadic cases for which
no mutations in the exons or introns of PITX2 have been found. The molecular genetics of some
ARS pedigrees should be re-examined with enzymes that can amplify medium and large genomic
fragments.
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Background
ARS is an autosomal dominant disorder characterized by
bilateral congenital abnormalities of the anterior segment
of the eye associated with abnormalities of the teeth, mid-
face, and umbilicus. These defects may include microdon-
tia, hypodontia, anodontia and maxillary hypoplasia.
Classic ocular features of ARS include iridocorneal syn-
echiae, iris hypoplasia, corectopia, polycoria, and/or
prominent anteriorly displaced Schwalbe's line (posterior
embryotoxon). Glaucoma develops in approximately
50% to 60% of patients with ARS. Axenfeld's and Rieger's
anomalies were originally described as separate clinical
entities. These and various abnormalities of the anterior
chamber of the eye are now considered to fall into the
same spectrum of developmental disorders, or even to be
variations of ARS [1].
ARS has been linked to five chromosomal loci (4q25,
6p25, 11p13, 13q14, 16q24) [2-4] Disease-causing muta-
tions have been identified in three transcription factor
genes. Two of these genes – PITX2 and FOXC1, which map
to chromosomes 4q25 and 6p25, respectively – are the
most frequently affected. Only one case of ARS caused by
deletion of the paired-box transcription factor, PAX6,
which maps to chromosome 11p13 has been reported [5].
The causal genes at chromosome 13q14 and chromosome
16q24 loci have not been identified.
The PITX2 gene (OMIM: 601542) was identified by posi-
tional cloning of the chromosome 4q25 locus and has
been implicated in ARS pathogenesis. The PITX2 gene has
seven exons [6] and encodes a member of the bicoid/
paired-like homeodomain family [7]. However, only 40%
of patients diagnosed with classical Rieger syndrome have
PITX2 mutations [4]. PITX2 haploinsufficiency may cause
this syndrome [8,9]
PITX2 clearly plays an important role in embryonic and
foetal development. PITX2 is also required for the normal
development of neurons in the mouse midbrain [8,9] and
is involved in pituitary gland development. Thus, brain
MRI in patients with ARS is justified.
New PITX2 mutations causing ARS have been reported
recently. More information can be found in the web data-
base [10].
We investigated the molecular basis of a severe form of
Axenfeld-Rieger Syndrome in one family for which no
mutation of PITX2 or FOXC1 was found. Our findings
from quantitative genomic PCR and additional experi-
ments indicate that a 3,059 bp intragenic deletion in the
PITX2 gene causes this unusual form of ARS.
Case presentation
We analysed one family in which two patients were
affected by an unusual form of ARS. The man (I-2) was 51
years old and presented with bilateral Axenfeld-Rieger
syndrome with hypodontia, maxillary hypoplasia and
redundant periumbilical skin. He had chronic glaucoma
that had been monitored clinically and surgically for at
least 10 years. During this period of follow-up, he had
undergone bilateral trabeculectomy.
An MRI scan carried out in June 2005 (Figure 1a) showed
a left frontal meningioma that was 4 mm in diameter and
atrophy of the two optic nerves in intraorbital sections.
We observed marked dilatation of the myelin sheaths
(Figure 1b). A second MRI scan in January 2006 showed
that the meningioma had doubled in size over seven
months.
This man also had severe thyroid problems with goiter
consisting of bulky nodules that were up to 3 cm in diam-
eter on both the right and left parts of the gland. He pre-
sented with hyperthyroidism that was not associated with
pituitary adenoma or functional pituitary hormonal
abnormalities.
This man's daughter (II-1) was 21 years old at the time of
the study. She presented with the same characteristic fea-
tures of ARS (Figure 2a and 2b), but had developed them
earlier. She had severe glaucoma resulting in the early
removal of the left eye and the fitting of a prosthesis. She
presented with no abnormality of the optic nerves or ret-
rochiasmatic visual pathways. Unlike her father, MRI
scans showed she had no signs of meningioma or optic
nerve abnormality.
MRI scan for patient I-2 Figure 1
MRI scan for patient I-2. A) Left frontal meningioma measur-
ing 4 mm in diameter. B) Atrophy of the two optic nerves in 
their intraorbital portions (before the intracanal portion) 
with dilatation of the sheaths.BMC Medical Genetics 2006, 7:82 http://www.biomedcentral.com/1471-2350/7/82
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The father's visual acuity was reduced to 20/200 in both
eyes, with only narrow parts of the visual field unaffected.
The daughter had poor visual acuity in her remaining eye,
limited to counting fingers. Slit lamp examination and
photographic imaging showed polycoria associated with
iridocorneal synechia and iris hypoplasia in both father
and daughter (Figure 2b). We also observed polycoria by
slit lamp examination and anterior optical coherent tom-
ography (Figure 3) with an OCT3 Stratus machine that
was defocused for anterior chamber examination. We saw
goniostrands and parts of the iris that were very near the
cornea in some sectors of the anterior chamber. This
severely reduced the iridocorneal angle and accounted for
the persistent high intraocular pressure (40 mmHg mini-
mum value) measured with a Goldmann aplanation
tonometer, despite previous trabeculectomy and ongoing
maximal anti-glaucomatous medical treatment. Both
patients were fully examined in the cardiology, pneumol-
ogy and endocrinology departments of our hospital.
Other than the thyroid abnormalities of I-2, which were
not of pituitary origin and were treated, the patients dis-
played no abnormalities.
Genetics analysis
Characterization of a deletion in the PITX2 gene
We looked in this family for PITX2 mutations (Figure 4a)
that might account for the unusual phenotype. We
screened the seven exons of the PITX2 gene by PCR with
different primers [11] [see Additional file 1] and by
sequencing, but found no mutation. We then searched for
an intragenic deletion in the PITX2 gene by quantitative
genomic PCR (Table 1) [12] with primer pairs designed
for the amplification of both exon 5 and exon 6. Both
these exons were present as a single copy. Each of the
affected patients had only one copy of the PITX2 gene. We
identified, in both patients, an intragenic deletion corre-
sponding to part of exon 5, intron 6 and part of exon 6.
We used two primers, one binding just before exon 5 (5'-
CAGCTCTTCCACGGCTTCT-3') and the other binding
just after exon 6 (5'-CTGTGGGTGCGGCTCACA-3'), to
amplify a fragment of DNA large enough to determine
accurately the start and end points for the intragenic dele-
tion. We amplified only a 3,331 base-pair (bp) fragment
from control genomic DNA from unaffected patients.
However, we amplified the 3,331 bp fragment and an
additional abnormal fragment of 272 bp from the
genomic DNA samples from of the patients with ARS (I-2
and II-1). The short fragment corresponded to the
genomic sequence of the abnormal partially deleted
PITX2 gene (Figure 5). We characterized this deletion by
sequencing the amplified fragments of genomic DNA
from controls and affected patients (Figure 4b and 4c).
The deletion began six nucleotides from the 5' end of exon
5 (5'-CTCCAG-3') and ended after the same repeated
sequence in exon 6. Thus, 3,059 bp between the nucle-
otides 18,183 to 21,242 within the PITX2  gene
(gi|13183092|gb|AF238048.1| [13183092]) were
deleted. This deletion removed the end of exon 5, the fol-
lowing intron and the beginning of exon 6 (Figure 6).
Consequently, the PITX2 genomic sequence spanning 144
of the 180 nucleotides of the homeobox sequence was
lost. Should the gene be transcribed and the correspond-
ing transcripts not degraded by nonsense-mediated
mRNA decay, they might be translated. The resulting
abnormal proteins would contain only the first twelve
amino acids of the PITX2 homeodomain. The homeodo-
main is present in the PITX2 A, B and C isoforms and con-
tains helix3, implicated in DNA binding. Thus, the
truncated homeodomain, lacking helix3, would not be
functional (Figure 6).
Phenotypic analysis of patient II-1 Figure 2
Phenotypic analysis of patient II-1. A) Panoramic dental X-ray 
showing hypodontia (arrow 1) and area of maxillary hypopla-
sia (arrow 2), B: Eye imaging showing polycoria.BMC Medical Genetics 2006, 7:82 http://www.biomedcentral.com/1471-2350/7/82
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Consequences of the intragenic deletion on the PITX2 
mRNA sequence
We investigated how the PITX2  intragenic deletion
affected the PITX2 mRNA sequence. For this purpose, we
sequenced PITX2 following RT-PCR from total RNA iso-
lated from lymphoblastoid cell lines established from the
two ARS-affected patients. The RT-PCR amplification was
done with primers that were unambiguously outside the
deletion area: P5, 5'-AGCGGACTCACTTTACCAGC-3',
was in exon 5 and P6, 5'-CCCACGACCTTCTAGCATAA-3',
was in exon 6. The amplified region is conserved in the
three PITX2 mRNA isoforms both from the DNA samples
of normal individuals and affected patients. The amplifi-
cation yielded one fragment of the expected size. No
abnormal fragments were detected (data not shown).
Thus, our findings support the notion that simple PITX2
haploinsufficiency causes the pathogenicity of the intra-
genic  PITX2  microdeletion in the eye and possibly in
other target tissues.
Discussion
We have analysed a family affected by an unusual form of
ARS. The difference in the phenotypes between I-2 and II-
1 is typical for this syndrome. A severe, acute increase in
OCT examination of patient II-1 Figure 3
OCT examination of patient II-1. A) Partial iris apposition to the cornea, decreasing the iridocorneal angle of the right eye. 
Presence of abnormal goniostrands.(arrow) B) Abnormal goniosynechiae associated with goniostrands in a supratemporal posi-
tion in the right eye (arrow). These structures significantly decrease the iridocorneal angle and clearly explain the very high 
intraocular pressure measured in this remaining eye. C) Polycoria with a heterogeneous iris and abnormal structure of the cor-
nea. An iridocorneal synechia is visible between the corneal endothelium (arrow 1) and the inner part of the iris (arrow 2). It 
appears to be the remnant of iris hypoplasia and contributes to polycoria. D) Visualization of abnormal goniostrands (arrow 1) 
and of an abnormal remnant iris bridge effected by partial hypoplasia (arrow 2).BMC Medical Genetics 2006, 7:82 http://www.biomedcentral.com/1471-2350/7/82
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intraocular pressure in II-1 had an effect similar to axot-
omy, with no optic nerve damage visible by MRI. How-
ever, a chronic increase in intraocular pressure that
progressed over a long period of time in I-2 triggered the
progressive disappearance of axons in the optic nerve,
with enlargement of the myelin sheath (Figure 1b) which
may have provided a degree of neuroprotection.
The atrophy of the optic nerve that was observed by MRI
in the father has not been reported previously in patients
with ARS. However, a recent study provides a possible
explanation for this observation. Mice in which the pitx2
gene has been specifically knocked out in the neural crest
have optic nerve atrophy [13]. This suggests that PITX2 is
involved in the formation of the optic nerve and/or its
susceptibility to high intraocular pressure. Together with
the findings of Ittner and al. and Berry and al [14,15],
these results strongly support the hypothesis that PITX2
regulates levels of extrinsic factor(s) required for optic
nerve development.
No other case of meningioma in association with ARS has
been reported. The occurrence of both meningioma and
ARS in I-2 may reflect an unlikely coincidence with these
conditions arising through different mechanisms. Patient
II-1, carrying the same mutation, had no signs of menin-
gioma when she was examined. We need to determine
whether this clinical observation results from deletion of
the PITX2 gene or whether it is an independent event. Var-
ious meningiomas have been associated with the translo-
cation of part of chromosome 4 to chromosome 22 [16],
but no direct relationship with the PITX2 gene was found.
Meningiomas are usually benign intracranial and intrasp-
inal tumors. However, invasive meningiomas can pene-
trate the brain parenchyma and disturb vital structures.
Meningioma cells are derived from the craniofacial neural
crest, which migrates around the anterior neural tube and
colonizes the head mesenchyma [17,18]. Therefore, men-
ingiomas have been suspected for a long time to express
genetic programmes similar to the foetal meninges. The
mouse ortholog of FOXC1, called Mf1, is expressed
strongly in the meninges [19,20]. Recently, PITX2A was
reported to function as a negative regulator of FOXC1
transactivation activity with its homeodomain [15]. The
FOXC1  gene expression pattern is modified in several
A) Genealogy of the family Figure 4
A) Genealogy of the family. B) Sequence of PITX2 in patient I-2. C) Normal sequence of PITX2 (patient I-1).BMC Medical Genetics 2006, 7:82 http://www.biomedcentral.com/1471-2350/7/82
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A) Schematic of PITX2 gene organisation Figure 6
A) Schematic of PITX2 gene organisation. Boxes represent 
exons, lines represent introns. We have indicated the sizes of 
exons and introns. The blue box represents the homeodo-
main. The hatched box represents the deleted sequence. B) 
Nucleotide sequences and corresponding amino acids.
Table 1: Dosage of the PITX2 gene was determined by genomic quantitative PCR. We used ALB and ERBB as endogenous DNA control 
genes. PITX2 is expressed from only one copy in patients I-2 and II-1, in contrast to what was observed for other members of the family 
(I-1 and II-2) and unrelated cases (856, 23128, 31964).
ALB PITX2 U2/L2
n Ct ∆ n Ct ∆ PITX2/ALB
I-1 21,1 118,6 21,9 8,8 0,7 1,1
I-2 20,8 144,3 22,6 5,2 0,4 0,5
II-1 20,5 180,4 22,7 4,9 0,3 0,4
II-2 21,5 90,5 22,3 6,6 0,7 1
856 21,6 86,2 22,3 6,5 0,8 1
23128 20,4 190,9 21,2 14,0 0,7 1
31964 20,5 179,1 2,4 12,5 0,7 1
ERBB PITX2 U2/L2
n Ct ∆ n Ct ∆ PITX2/ERBB
I-1 21,1 122,8 21,9 8,8 0,7 1,0
I-2 20,8 150,1 22,6 5,2 0,3 0,5
II-1 20,8 145,0 22,7 4,9 0,3 0,5
II-2 21,4 95,7 22,3 6,6 0,7 1,0
856 21,5 92,0 22,3 6,5 0,7 1,0
23128 20,2 221,3 21,2 14,0 0,6 0,9
31964 20,8 151,9 2,4 12,5 0,8 1,1
Agarose gel showing the deletion Figure 5
Agarose gel showing the deletion. The normal fragment is 
3,331 bp in length. The abnormal fragment is 272 bp in 
length.BMC Medical Genetics 2006, 7:82 http://www.biomedcentral.com/1471-2350/7/82
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human cancer cell lines [21-23]. A significant fraction of
primary cancers displays somatic mutations in this gene
encoding a member of the Forkhead transcription factor
family. Thus, FOXC1 may function as a tumour suppres-
sor gene, through TGF-β1-mediated signals [24]. The
FOXC1 transcription factor gene is critical for the forma-
tion of tissues derived from neural crest and mesenchymal
mesoderm cell lineages [20,25]. It was recently reported
that FOXC1 was associated with tumours originating from
the mesenchyme including synovial sarcomas [22]. The
FOXC1 gene and some of its target genes involved in the
TGFβ-1 pathway appear to be upregulated, as shown by
microarray experiments and RT-qPCR [22]. PITX2 serves
as a competence factor required for the temporally-
ordered and growth factor-dependent recruitment of a
series of specific coactivator complexes necessary for cyc-
lin D2 and cyclin D1 [26] gene induction. PITX2 gene
expression has been associated with cancerogenesis. It was
recently suggested that increases in PITX2 gene expression
leads to the nuclear accumulation of β-catenin in the
nuclei of pituitary cells, leading to malignant adenoma
[27,28]. PITX2 is also a target gene for the product of the
mixed lineage leukemia (MLL) gene [29]. The protein
encoded by the MLL gene is directly involved in acute leu-
kaemia associated with abnormalities in chromosome
11q23 in humans [30].
Now it appears that the amounts of the PITX2 and FOXC1
genes expressed are crucial for triggering developmental
or oncogenic abnormalities. Many lines of evidence have
identified PITX2 and FOXC1 as genes possibly involved,
primarily or secondarily, in the multistep processes of
cancerogenesis. Further studies should clarify the roles for
FOXC1 and PITX2 in human developmental processes
and oncogenesis [31]. Unexpected interactions between
PITX2 and FOXC1 proteins have been recently discovered
[15]. Currently, the molecular basis for ARS clinical man-
ifestations is thought to involve both increased and
decreased PITX2 and FOXC1 activity. Protein interactions
may explain the strict dosage sensitivity of PITX2  and
FOXC1: PITX2-PITX2 and PITX2-FOXC1 complexes may
form in a concentration and/or cofactor-dependent fash-
ion. Changes in the expression of either gene may alter the
relative abundance of both types of complex. If PITX2-
PITX2 and PITX2-FOXC1 complexes are mutually exclu-
sive, they may interact with distinct cofactors and/or acti-
vate different groups of target genes. Alternatively, PITX2-
PITX2 and PITX2-FOXC1 complexes may compete for a
common pool of transcriptional cofactors and/or binding
sites. The deletion identified in the family presented here
affected the C-terminal domain of PITX2 and is likely to
affect FOXC1 activity. Regulation through FOXC1-PITX2
interactions is complex. Thus, FOXC1/PITX2 mutations or
deletions may lead to the transcriptional dysregulation of
a subset of target genes and not only the loss of target gene
expression by either PITX2  or  FOXC1  alone. Thus,
depending on the cellular context, genetic alterations of
FOXC1 or PITX2 could result in the loss of transcriptional
activation or the loss of transcriptional repression of target
gene activity [15].
We did not detect aberrant forms of PITX2 in lymphoblas-
toid cell lines or in white blood cells. However, this does
not mean that the mutated PITX2 allele is not expressed in
vivo. The homeodomain of the abnormal PITX2 proteins
presumably produced in the affected patients might
include the first twelve amino acids of this domain. Nor-
mally, the PITX2 protein interacts with the FOXC1 protein
through its paired homeodomain. However, the PITX2-
FOXC1 interaction may not occur or could be very loose
in these ARS patients. The aberrant PITX2 proteins result-
ing from the possible translation of the shortened PITX2
mRNA isoforms might form complexes with normal
FOXC1 proteins and would not be able to impair FOXC1
activity. This would explain the severe phenotype
observed in both affected patients and the occurrence of a
meningioma in patient I-2.
FOXC1 seems to participate in several transcription factor
complexes including PBX1 [35]. Thus, it appears that the
pathophysiology of ARS and the diversity of clinical man-
ifestations observed in ARS-affected patients is caused by
complex abnormal transcriptional mechanisms and
abnormal (post) translational interactions between sev-
eral transcription factors and between the DNA/transcrip-
tion factor complexes. Whatever the cause of the
meningioma in patient I-2 and potentially in patient  II-1,
all patients with ARS should be monitored regularly by
brain and spine MRIs.
The most common cause of ARS is a mutation in the
PITX2 gene or in the FOXC1 gene. However, exon-by-exon
screening for mutations in genomic DNA may fail to
detect a mutant allele. This is illustrated by the case
reported here. There were no mutations detected in the
seven exons and adjacent introns of the PITX2 gene. The
most probable explanations for the apparent absence of
PITX2 gene alteration are that a large DNA rearrangement
was masked by the presence of the wild-type PITX2 nor-
mal allele or that there was an undetected mutation in an
intron. The absence of clinical abnormalities in the previ-
ous generation (data not shown) suggests that this may be
a de novo genomic alteration. Unfortunately, the grandpar-
ents of patient II-1 were not available for participating in
this study.
Following the detection of an intragenic PITX2 deletion
by quantitative genomic PCR, we developed a PCR proto-
col for amplifying exon 5, intron 6 and exon 6 to look for
DNA rearrangement. Fine mapping of the deletion break-BMC Medical Genetics 2006, 7:82 http://www.biomedcentral.com/1471-2350/7/82
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point by direct sequencing of the PCR products showed
that the deletion had removed a 3,059 bp region extend-
ing from the end of exon 5 to the start of exon 6. The junc-
tions at the beginning and end of the deletion contained
a short direct six bp repeat (CTCCAG). This is not the first
time that quantitative genomic PCR has been used to
detect  PITX2  deletions. However, only microdeletions
and gross deletions without refined molecular characteri-
zation have been reported [32]. The deletions reported
previously were not molecularly characterized and might
correspond to closely related syndromes [32]. Some
involved the loss of several genes and resembled the inter-
stitial microdeletions detectable by FISH. This is the first
report of an entirely intragenic PITX2 deletion, accurately
characterized, that does not lead to complete PITX2 gene
deletion. There are various possible explanations for this
intragenic deletion. All the proposed mechanisms for
deletions or other rearrangements in human genetic dis-
orders – including genomic disorders, a subset of genetic
disorders associated with large deletions and/or duplica-
tions – are associated with the presence of repetitive
sequences. One of these mechanisms is the slipped mis-
pairing hypothesis, first proposed by Streisinger [33] and
initially observed in yeast. The CTCCAG of exon 5 could
bind to the corresponding GAGGTC sequence in exon 6
on the other strand. This would result in the formation of
a single-stranded loop that could be excised by a DNA
repair enzyme, for example RAD [34]. Slipped mispairing
is probably the mechanism for the deletion reported in
this study (data not shown). However, we cannot rule out
the possibility that non-homologous end joining (NHEJ)
led to this deletion. The intragenic deletion in this family
resembles the haploinsufficency effects of most PITX2
mutations causing ARS [1].
Conclusion
Mutational status has been reported for many patients
with ARS. However, the overall detection rate for muta-
tions is low. This is the first time that an intragenic dele-
tion of the PITX2 gene has been identified, with a PCR
protocol designed to amplify larger genomic fragments
than those usually amplified for direct sequencing. The
detection and the characterization of such a deletion were
made possible by initial data provided by quantitative
genomic PCR. Genomic fragments of one to several kilo-
bases can be amplified with common Taq polymerase
enzymes with intron-spanning primers in classical PCR
reactions, facilitating the detection of medium sized intra-
genic deletions. The advent of new Taq polymerases
(TaKaRa La Taq enzyme Cambrex) for long-range PCR
and quantitative genomic PCR provide new tools for
detecting large intragenic deletions throughout an entire
gene. These tools, normal genomic PCR with intron span-
ning primers, and restriction enzymes will facilitate the
refinement of PITX2 mutation analysis and ARS molecu-
lar diagnosis. They should also increase the sensitivity of
genomic mutational screening. The screening of genes
upstream or downstream from PITX2 or FOXC1 in ARS-
affected families or in sporadic cases of ARS remains to be
explored.
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